Ask a Librarian

Threre are lots of ways to contact a librarian. Choose what works best for you.

HOURS TODAY

Closed

Reference Desk

CONTACT US BY PHONE

(802) 656-2022

Voice

(802) 503-1703

Text

MAKE AN APPOINTMENT OR EMAIL A QUESTION

Schedule an Appointment

Meet with a librarian or subject specialist for in-depth help.

Email a Librarian

Submit a question for reply by e-mail.

WANT TO TALK TO SOMEONE RIGHT AWAY?

Library Hours for Sunday, April 21st

All of the hours for today can be found below. We look forward to seeing you in the library.
HOURS TODAY
10:00 am - 12:00 am
MAIN LIBRARY

SEE ALL LIBRARY HOURS
WITHIN HOWE LIBRARY

MapsM-Th by appointment, email govdocs@uvm.edu

Media Services1:00 pm - 5:00 pm

Reference DeskClosed

OTHER DEPARTMENTS

Special CollectionsClosed

Dana Health Sciences Library9:00 am - 11:00 pm

 

CATQuest

Search the UVM Libraries' collections

UVM Theses and Dissertations

Browse by Department
Format:
Online
Author:
Bogart, Rebecca Jane
Dept./Program:
Chemistry
Year:
2023
Degree:
Ph. D.
Abstract:
Class B G-protein coupled receptors (GPCRs) are activated by the secretin/glucagon/VIP family of related peptides for physiological homeostasis. Importantly, the PAC1 and VPAC receptor subtypes, which recognize the pituitary adenylate cyclase activating peptide (PACAP) and vasoactive intestinal peptide (VIP), are involved in many central effects such as nociceptive sensitivity, learning/memory, and stress-associated behaviors. By targeting these receptors, small molecule antagonists that regulate signaling have therapeutic potential to mitigate maladaptive PACAP/PAC1 receptor signaling that may be contributory to a number of disorders including chronic pain, migraine and anxiety disorders including post-traumatic stress disorder. Identifying antagonists for the PAC1 receptor is complicated by the fact that there are no published full-length crystal structures of this receptor, which makes the rational design and development of small molecule therapeutics difficult. In spite of these challenges, several potent small molecule antagonists for the PAC1 receptor have been discovered and developed in the Brewer lab. Based on these scaffolds, we have performed extensive structure activity relationship studies to understand important motifs necessary for selective and potent binding at the PAC1 receptor. This work benefited from the collaboration with computational chemists and neuroscientists which aided in the discovery of the novel scaffolds through molecular modeling simulations and biological studies. Additionally, data from open field tests and elevated plus mazes confirm that pretreatment with our small molecule antagonists reduce PACAP-stimulated anxiety-like behavioral responses in rats. This thesis will describe our work that led to the identification of three novel scaffolds that act as small molecule antagonists of the PAC1 receptor RJB145, RJB248, and JF214. These compounds effectively block PAC1 receptor signaling in in vitro assays at low micromolar concentrations (IC50[less than or equal to]10[mu]M). RJB145 and JF214 have also been shown to mediate anxiety-like responses in rats in various behavioral models.
Note:
Access to this item embargoed until 10/05/2025.